Lung Cancer Clinical Trial
Official title:
A Phase II Randomized Cross-over Study of the Efficacy and Safety of Omega 3 Fatty Acid Supplements on Lung Cancer-Promoting Inflammatory Markers in Heavy Smokers
The study duration is 12 months. The initial enrollment visit will take approximately one hour. The Month 1, 3, 6, 7, 9 and 12 visits will take approximately 30 minutes each. The three telephone visits will take approximately 10 minutes each. The total time commitment to the study will be approximately four and a half hours.
The table below explains what will be done at each study visit:
Prior to Pre-Registration Informed Consent. Questionnaire (asking about your risks for lung
cancer, diet and medications including food supplement). Blood test for CRP level
Prior to Registration/Randomization Blood test for CRP level (about 6 ml or 1 teaspoon)
Pregnancy test (either blood or urine, for woman with childbearing potential only)
Registration/Randomization Medical history Physical exam (Vital signs/Body height and weight)
Receive 3 month supply of Omega 3 fatty acids for treatment first group. Blood tests for
Fasting Blood insulin, etc (about 15 ml or 3 teaspoons) Receive a diary to record the amount
of study medication you take each day and any side effects you may experience
Week 2 telephone interview Ask about side effects you may be having Ask about other
medications you may be taking Review study agent diary
Month 1 visit (you will not be able to eat anything for 10 hours before the appointment)
Blood test for Fasting Blood insulin, etc (15 ml or 3 teaspoons) -( All participants)
Treatment Group:
Ask about side effects you may be having Ask about other medications you may be taking Review
study medication diary
Month 2, 4, and 5 telephone interview Review diary Ask about side effects you may be having
Ask about other medications you may be taking
Month 3 visit (you will not be able to eat anything for 10 hours before the appointment)
Physical exam with vital signs Repeat blood tests (about 15 ml or 3 teaspoons) (All
participants)
Treatment Group:
Collect unused omega 3 (for treatment group) Receive next 3 month supply of omega 3 (for
treatment group) Review study medication diary Ask about side effects you may be experiencing
Ask about other medications you may be taking
Month 6 or end of study visit (if left study early for any reason) Physical exam with vital
signs Blood tests (about 15 ml or 3 teaspoons) - All participants
Treatment Group:
Review and collect study agent diary Ask about side effects you may be having Ask about other
medications you may be taking
Month 7-12 Cross over study Treatment group will become observation group Observation group
will become treatment group with the same procedures in month 1 to 6
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|